Valneva SE (VALN) Goodwill & Intangibles (2019 - 2026)
Valneva SE (VALN) posted Goodwill & Intangibles of $25.3 million for Q1 2026, down 2.66% sequentially from $26.0 million in Q4 2025, and down 2.12% YoY from $25.9 million in Q1 2025.
Analysis
Valneva SE (VALN) Goodwill & Intangibles (2019 - 2026) Analysis & Trends
Valneva SE has reported Goodwill & Intangibles for 8 years, with the latest figure at $25.3 million in Q1 2026.
- Quarterly Goodwill & Intangibles fell 2.12% year-over-year to $25.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.3 million (down 2.12% YoY) and the FY2025 annual result came in at $26.0 million, down 4.84% from the prior year.
- Goodwill & Intangibles fell to $25.3 million in Q1 2026 per VALN's latest filing, from $26.0 million in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $36.8 million in Q3 2024 and troughed at $25.3 million in Q1 2026.
- A 5-year average of $28.9 million and a median of $27.5 million in 2023 frame the typical range for Goodwill & Intangibles.
- The sharpest annual moves came in 2024 and 2025: Goodwill & Intangibles gained 28.22% in 2024, then decreased 26.63% in 2025.
- Over 5 years, Goodwill & Intangibles stood at $29.3 million in 2022, then declined by 6.09% to $27.5 million in 2023, then retreated by 1.88% to $27.0 million in 2024, then declined by 3.61% to $26.0 million in 2025, then dropped by 2.66% to $25.3 million in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $25.3 million, $26.0 million, and $27.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24.31 Mn |
| Mar 31, 2026 | 25.32 Mn |
| Dec 31, 2025 | 26.02 Mn |
| Sep 30, 2025 | 26.97 Mn |
| Jun 30, 2025 | 26.97 Mn |
| Mar 31, 2025 | 25.87 Mn |
| Dec 31, 2024 | 26.99 Mn |
| Sep 30, 2024 | 36.77 Mn |
| Jun 30, 2024 | 26.05 Mn |
| Mar 31, 2024 | 27.00 Mn |
| Dec 31, 2023 | 27.51 Mn |
| Sep 30, 2023 | 28.67 Mn |
| Jun 30, 2023 | 29.54 Mn |
| Mar 31, 2023 | 29.94 Mn |
| Dec 31, 2022 | 29.29 Mn |
| Sep 30, 2022 | 29.90 Mn |
| Jun 30, 2022 | 32.77 Mn |
| Mar 31, 2022 | 35.65 Mn |
| Dec 31, 2021 | 37.41 Mn |
| Dec 31, 2020 | 42.22 Mn |